Urine metallomics signature as an indicator of pancreatic cancer. Issue 5 (25th March 2020)

• Record Type: Journal Article
• Authors: Schilling, Kathrin; Larner, Fiona; Saad, Amina; Roberts, Rhiannon; Kocher, Hemant M.; Blyuss, Oleg; Halliday, Alex N.; Crnogorac-Jurcevic, Tatjana
• Is Part Of: Metallomics. Volume 12:Issue 5(2020)
• Page Start: 752
• Page End: 757
• Publication Date: 2020-03-25
• Subjects: Metals -- Physiological effect -- Periodicals; 572.51
• DOI: 10.1039/d0mt00061b
• Languages: English
• ISSNs: 1756-5901

Abstract

Abstract : Urine metallomics as potential diagnostic tool for PDAC, one of the deadliest types of cancer. Abstract : Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer. Its high mortality rate is attributed largely to the difficulty of early diagnosis. Analysis of urine is an excellent non-invasive approach to trace changes in biochemical reactions due to cancer development. Here we show remarkable differences in concentration of several essential metals: significantly lower levels of urinary calcium and magnesium and increased levels of copper and zinc in PDAC when compared to healthy controls, and demonstrate that a combined analysis of these essential metals are accurate indicators (sensitivity = 99.5%) for metal dyshomeostasis in PDAC. In addition, natural stable zinc isotope composition ( δ 66/64 Zn) in urine reveals the preferential excretion of isotopically light zinc in PDAC ( δ 66/64 Znmedian = −0.15‰) compared to healthy controls ( δ 66/64 Znmedian = +0.02‰), likely supporting the dysregulation of metalloproteins. These findings demonstrate for the first time that metallomics is a promising approach for discovery of biomarkers for detection of patients with PDAC, completely non-invasively, using urine samples.